$PFE (Pfizer Inc.)

$PFE {{ '2015-07-28T15:23:21+0000' | timeago}} • Webcast

$PFE 2Q15 Q&A: Anderson of Bernstein asked an update on Enbrel. Geno replied that Enbrel continues to do well, 2% operational growth outside US on a large base. Overall, the company is not seeing or expecting a major shift in the Enbrel business related to the Remicade biosimilar, added Geno.

$PFE {{ '2018-01-04T13:11:11+0000' | timeago}} • Announcement

Arvinas LLC collaborates with $PFE for the discovery and development of drug candidates using Arvinas' PROTAC Platform, a novel technology used to create small molecule therapeutics aimed at degrading disease-causing cellular proteins. Arvinas may receive up to $830MM in upfront and potential development and commercialization milestone payments.

$PFE {{ '2017-12-26T12:25:28+0000' | timeago}} • Announcement

$PFE and $MRK announced that the US FDA has approved STEGLATRO (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets for adults with type 2 diabetes.

$MRK {{ '2017-12-22T16:34:34+0000' | timeago}} • Announcement

$MRK and $PFE announced that the FDA approved STEGLATROTM (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets.

$PFE {{ '2017-12-21T21:14:41+0000' | timeago}} • Announcement

$PFE announced that the US FDA has granted Breakthrough Therapy Designation for avelumab in combination with INLYTA for treatment-naive patients with advanced renal cell carcinoma (RCC). This is the second Breakthrough Therapy Designation granted to avelumab.

$PFE {{ '2017-12-20T12:23:04+0000' | timeago}} • Announcement

The US FDA has approved $PFE's supplemental New Drug Application to expand the indication for BOSULIF  to include adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph CML).

$PFE {{ '2017-12-18T19:31:58+0000' | timeago}} • Announcement

The BoD of $PFE has increased the quarterly dividend by 6% to $0.34 per share. The first quarter 2018 cash dividend will be payable on March 1, 2018, to shareholders of record on Feb. 2, 2018. The board also authorized a new $10Bil share repurchase program, in addition to the $6.4Bil remaining under the current authorization.

$LLY {{ '2017-12-11T17:36:13+0000' | timeago}} • Announcement

FDA accepts to review $LLY's Galcanezumab, an injectionable drug for the treatment of migraine. Rivals $NVS and $AMGN already filed their migraine drug with FDA in July 2017, while $TEVA is also expected to join the race. Lilly's pain portfolio also includes Tanezumab, developed in partnership with $PFE, for the treatment of osteoarthritis.

$JCI {{ '2017-12-11T16:43:09+0000' | timeago}} • Announcement

$JCI's BoD appointed John Young to serve as a director. Young is currently group president of $PFE Essential Health. Effective Jan. 1, 2018, he will become group president of Pfizer Innovative Health, which comprises six business groups focused on improving health through innovative products covering every stage of life.

$PFE {{ '2017-12-01T11:52:44+0000' | timeago}} • Announcement

$PFE enters into agreement with Basilea Pharmaceutica Ltd to develop and commercialize CRESEMBA in China and Asia Pacific region. CRESEMBA is a novel antifungal medicine for the treatment of adult patients with diagnosed invasive aspergillosis and mucormycosis.

$PFE {{ '2017-11-17T11:53:03+0000' | timeago}} • Announcement

The US FDA has approved a new use for $PFE’s cancer drug SUTENT. The drug was approved as an adjuvant in renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney).

$PFE {{ '2017-11-13T15:41:23+0000' | timeago}} • Announcement

$PFE has named Albert Bourla as COO effective Jan. 1, 2018. Also effective Jan. 1, John Young, Group President, Pfizer Essential Health will become Group President, Pfizer Innovative Health. Angela Hwang, Global President and General Manager for Pfizer Inflammation & Immunology will succeed John Young as Group President, Pfizer Essential Health.

$PFE {{ '2017-11-07T13:59:46+0000' | timeago}} • Webcast

$PFE welcomes the potential changes in drug distribution models. With $AMZN considering an entry into the pharmacy space, CEO Ian Read on the company's 3Q17 earnings call said, “Any system of distribution that can cut costs and get a wide availability of products to patients is something that the whole industry would be interested.”

$PFE {{ '2017-11-07T13:49:05+0000' | timeago}} • Webcast

$PFE’s Innovative Health business had strong 3Q17, driven by continued growth of key brands, including Ibrance and Eliquis globally and Xtandi, Lyrica, Xeljanz and Chantix in the US. On the other hand, Essential Health business saw revenue declining in the quarter, but had strong operational growth in emerging markets and in biosimilars portfolio.

$PFE {{ '2017-10-31T14:38:09+0000' | timeago}} • Announcement

$PFE's Innovative Health division, which sells newer, patent-protected medicines, posted an 11% increase in revenue for 3Q17, while Essential Health, that sells older drugs, fell 12%. The company lifted its FY17 EPS forecast to $2.58-2.62 from the previous range of $2.54-2.60, with revenue ranging between $52.4Bil and $53.1Bil.

$PFE {{ '2017-10-31T14:24:43+0000' | timeago}} • Announcement

With slightly higher sales and lower one-time charges, $PFE saw its profit double for 3Q17 to $2.8Bil, or $0.47 per share, from $1.35Bil, or $0.22 per share, a year ago. Revenue edged up nearly 1% to $13.2Bil, driven by higher sales from most of its key new drugs, including cancer medicine Ibrance that grew 60% YoY.

$PFE {{ '2017-10-31T12:07:05+0000' | timeago}} • Infographic

$PFE Pfizer Inc. Earnings AlphaGraphic: Q3 2017 Highlights

$JNJ {{ '2017-10-17T19:25:16+0000' | timeago}} • Webcast

$JNJ said, "The key factor to Remicade being successful is physicians and patients have a high confidence in it based on experience that they don't want to switch to an alternative." The company was responding to a question on rival $PFE's lawsuit against it for allegedly using unfair means to protect Remicade from competitors.

$AGN {{ '2017-10-12T22:44:22+0000' | timeago}} • Announcement

$AGN, which inked a controversial patent deal with Mohawk Tribe, reached a patent litigation settlement on its dry eye treatment drug Restasis with InnoPharma, a unit of $PFE. The litigation, which was filed in Sept. 2015 by Allergan, will be withdrawn and Allergan will grant license to InnoPharma to market Restasis from Feb. 2024 or earlier.

$LLY {{ '2017-09-28T21:06:48+0000' | timeago}} • Announcement

FDA approves $LLY's breast cancer drug Verzenio (abemaciclib), which will compete with $PFE's Ibrance and $NVS' Kisqali drugs. Verzenio works by blocking certain molecules involved in promoting the growth of cancer cells. The National Cancer Institute estimated that approximately 252,710 women will be diagnosed with breast cancer this year.

$PFE {{ '2017-09-27T12:44:41+0000' | timeago}} • Announcement

$PFE declared 4Q17 dividend of $0.32 per share, payable Dec. 1, 2017, to shareholders of record at the close of business on Nov. 10, 2017. This cash dividend will be the 316th consecutive quarterly dividend paid by the company.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
BTX (BioTime, Inc.)
Thursday, November 9 2017 - 9:30pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
PCRX (Pacira Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
VCEL (Vericel Corporation)
Tuesday, November 7 2017 - 1:00pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
DRRX (DURECT Corporation)
Wednesday, November 1 2017 - 8:30pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
PFE (Pfizer Inc.)
Tuesday, October 31 2017 - 2:00pm
ARRY (Array BioPharma Inc.)
Tuesday, October 31 2017 - 1:00pm
CRY (CryoLife Inc.)
Tuesday, October 31 2017 - 12:00pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, October 26 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm
ALKS (Alkermes plc)
Thursday, October 26 2017 - 12:30pm
ABT (Abbott Laboratories)
Wednesday, October 18 2017 - 1:00pm

AlphaGraphics you may like